Lentiviral Vector Production via Baculovirus Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of replication-defective lentiviral vectors for large-scale clinical use is challenging due to the toxicity of lentiviral protease and fusogenic envelope proteins like VSV-G, and existing transient transfection systems are time-consuming and problematic, limiting the scalability and safety of lentiviral vector production.
Innovation Solution
The method involves cloning lentivirus transfer constructs, gag, pol, and envelope proteins into baculoviruses and transducing producer cells with these recombinant baculoviruses to generate functional lentiviral vectors, which can be pseudotyped with heterologous proteins for improved safety and scalability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If transient transfection systems are used for lentiviral vector production, then production flexibility is improved, but production time and operational complexity increase
Solution Approach 1:
The patent applies preliminary action by pre-establishing stable producer cell lines that already contain integrated lentiviral vector production constructs. These cell lines are prepared in advance and can be rapidly expanded and used for production without requiring time-consuming transient transfection procedures each time vectors are needed, thus reducing production time while maintaining flexibility
Solution Approach 2:
The patent uses copying by creating stable cell lines that serve as reusable templates for lentiviral vector production. Once a stable producer cell line is established, it can be repeatedly used to produce multiple batches of lentiviral vectors through simple passaging and induction, eliminating the need to repeat complex transfection procedures and significantly reducing production time
2Productivity
If constitutive vector production is attempted, then productivity is improved, but cell toxicity increases due to lentiviral protease and VSV-G
Solution Approach 1:
The patent applies segmentation by dividing the lentiviral vector production system into separate modular components: the transfer vector construct, the packaging plasmid (gag-pol), and the envelope glycoprotein plasmid (VSV-G). These can be produced in separate stable cell lines and then combined in a controlled manner, allowing high productivity while managing toxicity by controlling the timing and conditions of component mixing
Solution Approach 2:
The patent implements periodic action by using inducible promoter systems that allow controlled, periodic expression of viral components. The promoter can be induced at specific time points to trigger vector production, enabling constitutive-like productivity while limiting continuous toxic exposure by having defined production windows followed by rest periods for cell recovery
3Object-affected harmful factors
If VSV-G is replaced with less toxic glycoproteins, then cell toxicity is reduced, but transduction range and viral stability decrease
Solution Approach 1:
The patent applies universality by designing a modular envelope glycoprotein system where different glycoproteins can be interchanged in the same stable producer cell line framework. This allows selection of less toxic alternatives when needed while maintaining the ability to use VSV-G or other glycoproteins when broad transduction range is required, making the system universally applicable to different toxicity and transduction range requirements
Data Source
AI summary
Novel forward primer, reverse primer and poly-linker suitable for replication of nucleic acids in e.g., 293 cells.